ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
Information source: Sanofi
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoporosis
Intervention: Risedronate (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Sanofi Official(s) and/or principal investigator(s): Jean-Marc Chantelot, MD, Study Director, Affiliation: Sanofi
Summary
To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of
post-menopausal osteoporosis. Open, non-controlled, multi-center study.
Clinical Details
Official title: Record on Satisfaction of Patients With Actonel 35 mg Once a Week
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Patient satisfaction and compliance
Eligibility
Minimum age: 55 Years.
Maximum age: 80 Years.
Gender(s): Female.
Criteria:
Inclusion criteria :
- Postmenopausal ambulatory women
- Established osteoporosis
Exclusion criteria:
- History of cancer: basal cell or squamous cell carcinoma-documented 6-month
remission,
- Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Locations and Contacts
Sanofi-Aventis, Natanya, Israel
Additional Information
Starting date: May 2005
Last updated: September 24, 2009
|